Nevro Announces Settlement of IP Litigation with Nalu Medical

Nevro and Nalu Reached an Agreement to Dismiss Ongoing Litigation Premised on Nalu Medical No Longer Offering a High Frequency SCS Therapy

News provided by

Nevro Corp.

Dec 21, 2021, 16:05 ET

REDWOOD CITY, Calif., Dec. 21, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced the settlement of its patent lawsuit with Nalu Medical.

In February 2020, Nevro filed a patent lawsuit against Nalu Medical, accusing Nalu Medical of infringing Nevro's patents directed to high frequency spinal cord stimulation (SCS) therapy. As part of the litigation, Nevro was seeking injunctive relief to prevent Nalu from commercializing certain high frequency spinal cord stimulation therapies. Nalu represents that it does not currently offer SCS therapy that contains high frequency waveforms, nor does it have plans to commercialize high frequency waveforms in the future and, on that basis, the parties reached a mutual agreement that avoids the expense of any further litigation.

"We are very pleased with this outcome," said Kashif Rashid, Nevro's General Counsel. "Over the years, Nevro has made sizeable investments in developing and protecting its core intellectual property and this settlement represents the third time we have been able to successfully prevent a competitor from infringing our high frequency patents. That we are able to reach an efficient conclusion to this litigation, wherein we maintain the exclusivity of our high frequency SCS therapy while avoiding the expense of protracted litigation, is the best possible outcome."

"Nevro continues to be the only SCS company that can offer high frequency SCS therapy," said D. Keith Grossman, Nevro's Chairman, CEO and President. "Nevro's high frequency therapy is also the only FDA-approved SCS treatment option for painful diabetic neuropathy. With this litigation behind us, we can better focus our resources on continuing to develop and deliver life-changing solutions to our current and future patients."

Internet Posting of Information

Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. Nevro's proprietary 10 kHz Therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy.

SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, HFX, the HFX logo, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp.

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Investors and Media:
Julie Dewey, IRC
Nevro Corp.
Vice President, Investor Relations & Corp Communications
650-433-3247 | [email protected]

SOURCE Nevro Corp.